Celgene, Novartis File Ritalin Patent Suit

Law360, New York (November 2, 2007, 12:00 AM EDT) -- Pharmaceutical companies Celgene Corp. and Novartis AG continue to fight back against attempts to market a generic time-release version of Ritalin, a drug used to treat attention deficit/hyperactive disorder.

The companies filed a suit Wednesday against Barr Laboratories, Inc. in the U.S. District Court for the District of New Jersey. The legal battle follows a similar suit the companies filed against generics maker Abrika Pharmaceuticals Inc. in February.

The suit was filed after Barr filed an Abbreviated New Drug Application to market generic capsules of Ritalin...
To view the full article, register now.